➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

DARZALEX Drug Profile

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Tradename: DARZALEX

Patents:	14
Applicants:	1
BLAs:	2
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for DARZALEX

Recent Clinical Trials for DARZALEX

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Janssen Pharmaceuticals	Phase 2
Emory University	Phase 2
Fondazione Italiana Linfomi ONLUS	Phase 2

See all DARZALEX clinical trials

Pharmacology for DARZALEX

Ingredient-type	Antibodies, Monoclonal
Mechanism of Action	CD38-directed Antibody Interactions

Patent Text Search: US Patents for DARZALEX

These patents were identified by searching patent claims

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Janssen Biotech	DARZALEX	daratumumab	INJECTABLE;INJECTION	761036	001	2015-11-16	Start Trial	AbbVie Stemcentrx LLC (North Chicago, IL)	2033-02-08	RX	Orphan	search
Janssen Biotech	DARZALEX	daratumumab	INJECTABLE;INJECTION	761036	001	2015-11-16	Start Trial	Advenchen Pharmaceuticals, LLC (Moorpark, CA)	2035-05-04	RX	Orphan	search
Janssen Biotech	DARZALEX	daratumumab	INJECTABLE;INJECTION	761036	001	2015-11-16	Start Trial	The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) Janssen Biotech, Inc. (Spring House, PA)	2034-06-16	RX	Orphan	search
Janssen Biotech	DARZALEX	daratumumab	INJECTABLE;INJECTION	761036	001	2015-11-16	Start Trial	Mayo Foundation for Medical Education and Research (Rochester, MN)	2034-06-16	RX	Orphan	search
Janssen Biotech	DARZALEX	daratumumab	INJECTABLE;INJECTION	761036	001	2015-11-16	Start Trial	Cipla Limited (Mumbai, IN)	2036-06-30	RX	Orphan	search
Janssen Biotech	DARZALEX	daratumumab	INJECTABLE;INJECTION	761036	001	2015-11-16	Start Trial	ALX ONCOLOGY INC. (Burlingame, CA)	2035-08-07	RX	Orphan	search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patents for DARZALEX

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Japan	2018506293	Start Trial
China	110294741	Start Trial
Israel	254214	Start Trial
Hong Kong	1218930	Start Trial
Australia	2016257816	Start Trial
Eurasian Patent Organization	201792355	Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey

McKesson

Moodys

Merck

Colorcon

Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.